Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Study on Investigational Medication for Newly Diagnosed Immune Thrombocytopenia
Brief description of study.
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Immune Thrombocytopenia
-
Age: 1 years - 17 years
-
Gender: All
This study investigates the effectiveness of an investigational medication for patients with newly diagnosed Immune Thrombocytopenia (ITP). ITP is a condition where the immune system attacks and destroys platelets, which are cells in the blood that help with clotting. This study aims to compare the investigational medication with the standard treatment to see if it is as effective.
Participants in this study will receive either the investigational medication or the standard treatment as part of their care. The study will monitor how well the treatments work and their effects on the participants' platelet counts.
- Who can participate: Individuals who have been diagnosed with ITP within the last 3 months and require treatment according to their doctor can participate.
- Study details: Participants will receive either the investigational medication or the standard treatment. The study will compare the effects of these treatments on platelet counts.
Find a site
,
Since this trial requires contact information verification, you will receive an email with the information you provided asking for your validation. Only after this verification step your referral will be sent to the study site selected.
To verify your phone, please use one of the verification methods below:
,
,
Send a message
Enter your contact details to connect with study team
